The paraoxonase-1 (PON1) gene produces an enzyme that travels on HDL particles¹¹ HDL particles
High-density lipoprotein — the so-called "good cholesterol," which carries cholesterol from peripheral tissues to the liver and provides antioxidant protection in the arterial wall and acts as the bloodstream's primary defense against oxidized LDL — the form of "bad cholesterol" that initiates plaque buildup in artery walls. Three polymorphisms in the PON1 promoter region jointly regulate how much of this enzyme your liver produces: -108C/T (rs705379), -162A/G (rs705381), and -909G/C (rs854572). While the -108 position is the strongest single predictor of expression levels, the -909 variant tagged by rs854572 contributes independently to inter-individual variation and participates in the overall promoter haplotype.

The Mechanism

The PON1 gene sits on the minus (reverse) strand of chromosome 7q21.3. In the promoter region 909 base pairs upstream of the coding sequence, a G-to-C transition (reported as C>G in plus-strand genome files) alters a regulatory element that influences PON1 transcription. Functional studies by Brophy et al. (2001)²² Brophy et al. (2001)
Brophy VH et al., Pharmacogenetics 2001 demonstrated that the -909, -162, and -108 polymorphisms each have approximately a 2-fold effect on PON1 expression in reporter gene assays, though their effects appear context-dependent and not strictly additive. In a larger population study, the -909 variant showed strong linkage disequilibrium with the -108 and -162 sites, with no significant independent in vivo effect detectable in isolation in white individuals — suggesting that most of its influence on PON1 activity is propagated through the haplotype it tags rather than through a fully autonomous regulatory element.

However, expanded genetic analysis of the PON gene cluster by Carlson et al. (2012)³³ Carlson et al. (2012)
Carlson CS et al., Circ Cardiovasc Genet 2012 identified rs854572 as the lead SNP for arylesterase activity in a multi-SNP model, with the minor allele increasing activity by approximately 16% per copy — a finding that held even after accounting for the four classical functional SNPs (L55M, Q192R, -108, and -162). This suggests rs854572 captures regulatory variance that the other known variants do not fully explain, even if its independent effect is modest compared to the -108 position.

The Evidence

The clinical consequences of the -909 haplotype have been examined in cardiovascular, neurological, and ocular contexts.

In a prospective study of young coronary patients, Deakin et al. (2002)⁴⁴ Deakin et al. (2002) found that high-expressor PON1 promoter genotypes — including the -909 GG genotype (coding strand notation) — were associated with reduced risk of vascular disease in patients under age 60, consistent with higher promoter-driven PON1 output providing meaningful protection during the critical period of atherosclerotic plaque initiation.

In a measure of serum PON1 concentration in 417 coronary heart disease patients and 282 controls, PON1 concentration in the CHD group differed significantly by -909 genotype in the order GG > GC > CC (coding-strand notation), confirming the expression gradient this promoter variant creates.

A nutrigenetic study by Mancini et al. (2016)⁵⁵ Mancini et al. (2016)
Journal of Translational Medicine found rs854572 protective genotypes were significantly associated with increased HDL cholesterol levels specifically under high polyphenol and anthocyanin intake — suggesting an important gene-diet interaction where the expression effect of this variant is amplified in high-polyphenol dietary contexts. The association reached Bonferroni significance (Beta = 3.94 per protective allele).

Neurologically, rs854572 was highlighted as being in strong LD with rs854571, itself significantly associated with Parkinson's disease protection (p = 0.007) — Belin et al. (2012)⁶⁶ Belin et al. (2012)
Neuroscience Letters specifically noted rs854572 as reported to increase PON1 gene expression, and proposed the two variants together define the high-expression haplotype associated with neuroprotection.

Importantly, despite these activity associations, larger studies including Carlson et al. (2012)⁷⁷ Carlson et al. (2012) found no significant association between rs854572 and vascular disease endpoints (coronary artery disease, myocardial infarction) in population-level analyses. This suggests the modulation of PON1 activity by this variant is real, but insufficient alone to translate to detectable disease-level effects in unselected populations — the overall activity difference may require compounding with other PON1 variants or environmental exposures to reach clinical threshold.

Practical Implications

Because rs854572 operates as part of the broader PON1 promoter haplotype, its practical importance is highest in individuals who also carry unfavorable -108 or -162 variants, or the low-activity coding variants Q192R (rs662) or L55M (rs854560). For GG individuals (the low-expression plus-strand genotype), the priority interventions are those that upregulate PON1 expression through dietary means.

Dietary polyphenols have been shown in multiple controlled studies to increase PON1 expression and arylesterase activity — pomegranate juice, extra virgin olive oil, green tea, and quercetin-rich vegetables are the best-documented sources. The nutrigenetic study by Mancini et al. (2016) provides specific evidence that rs854572 carriers respond to polyphenol intake with measurable HDL changes, making dietary optimization particularly relevant for this genotype.

Interactions

rs854572 operates within the three-variant PON1 promoter haplotype block alongside rs854571 (immediately adjacent, also a promoter regulatory SNP) and rs705379 (-108C/T, the strongest determinant of PON1 expression). These promoter variants collectively control how much PON1 is produced, independently of the coding variants rs662 (Q192R, which controls enzyme catalytic specificity) and rs854560 (L55M, which affects protein stability and circulating concentrations). Individuals carrying unfavorable variants across all five PON1 positions represent the lowest-activity phenotype. The combined effect of this promoter variant with rs662 and rs854560 is of particular interest for compound action consideration, as the promoter-coding interaction determines both the quantity and quality of available PON1 enzyme simultaneously.

Cathepsin S (CTSS) is a lysosomal cysteine protease with an indispensable role at the heart of adaptive immunity: it is the primary enzyme that cleaves the invariant chain (Ii/CD74) from MHC class II molecules¹¹ MHC class II molecules
MHC class II is the cellular machinery that presents antigens to CD4+ T helper cells, initiating and shaping immune responses, enabling antigen loading and T-cell activation. When CTSS function is altered — whether by genetic variation or pathological upregulation — the cascade of T-cell priming and inflammatory cytokine production shifts in ways that promote atopic disease. This variant in the CTSS locus was identified as a novel atopic dermatitis risk locus in a large GWAS meta-analysis, underscoring a fundamentally immunological origin for eczema susceptibility.

The Mechanism

In professional antigen-presenting cells (dendritic cells, B cells, and macrophages), CTSS is the rate-limiting protease for removing the invariant chain from MHC class II molecules inside endosomes. Without efficient CTSS activity, peptide loading onto MHC class II is impaired; with excess CTSS activity, antigen presentation is amplified and self-tolerance can break down. Cathepsin S-deficient mice accumulate Ii-MHC II complexes and show severely impaired CD4+ T-cell responses²² Cathepsin S-deficient mice accumulate Ii-MHC II complexes and show severely impaired CD4+ T-cell responses
Riese et al. demonstrated that specific cathepsin S inhibition in B lymphoblastoid cells prevented complete proteolysis of the invariant chain and blocked SDS-stable peptide-loaded complexes.

Beyond its role in classical antigen presentation, CTSS is also secreted extracellularly by skin-resident dendritic cells and keratinocytes, where it activates proteinase-activated receptor 2 (PAR2)³³ activates proteinase-activated receptor 2 (PAR2)
PAR2 activation by CTSS triggers downstream TRPV1 signaling in sensory neurons on sensory nerve endings — directly triggering itch. This dual role in both antigen presentation and pruritus makes CTSS a mechanistically coherent risk gene for atopic dermatitis, which is defined by both immune dysregulation and chronic itch.

The rs187080438 T allele is an intronic variant in the flanking RPRD2 gene approximately 328 kb upstream of CTSS on chromosome 1q21. Although the variant itself does not alter any CTSS protein residue, GWAS loci routinely act through cis-eQTL mechanisms⁴⁴ cis-eQTL mechanisms
expression quantitative trait loci regulate the level of nearby gene transcription in a tissue-specific manner, commonly in immune cell types that alter gene expression levels, particularly in the immune cell types where CTSS is most active. The full mechanistic link between this specific intronic variant and CTSS expression changes in human immune cells awaits functional follow-up.

The Evidence

Budu-Aggrey et al. (2023, Nature Communications)⁵⁵ Budu-Aggrey et al. (2023, Nature Communications)
European and multi-ancestry genome-wide association meta-analysis of atopic dermatitis highlights importance of systemic immune regulation. Nat Commun. 2023;14(1):6280 conducted a GWAS meta-analysis including 65,107 atopic dermatitis cases and 1,021,287 controls in the European discovery phase, plus a multi-ancestry expansion to 765,209 individuals. Rs187080438 emerged as one of 29 novel loci genome-wide (OR=1.17, 95% CI 1.11–1.23, p=3.7×10⁻¹⁰). The finding replicated robustly in an independent 23andMe European cohort of 2,904,664 individuals (OR=1.14, p=2.0×10⁻⁴¹), making false-positive inflation highly unlikely. The CTSS gene was nominated as the most biologically plausible candidate given its tissue expression profile and established role in immune regulation.

The animal model evidence is compelling: Kim et al. (2012)⁶⁶ Kim et al. (2012)
Overexpression of cathepsin S induces chronic atopic dermatitis in mice. J Invest Dermatol. 2012;132(4):1169–76 showed that CTSS-overexpressing transgenic mice spontaneously develop a chronic atopic dermatitis-like skin disorder with PAR-2 upregulation, scratching behavior, and altered T-helper cytokine profiles. Separately, Chung et al. (2019)⁷⁷ Chung et al. (2019)
Cathepsin S acts via protease-activated receptor 2 to activate sensory neurons and induce itch-like behaviour. Neurobiol Pain. 2019 established the itch pathway: injected human recombinant CTSS caused dose-dependent scratching in mice that was abolished by PAR2 antagonists and reduced 50% in TRPV1-knockout mice. This convergent evidence — GWAS signal, transgenic mouse model, mechanistic itch pathway — places CTSS among the more biologically grounded novel AD loci. The evidence level is rated moderate: the GWAS association is well-powered and replicated, but functional confirmation of rs187080438's effect on CTSS expression in human tissue is not yet published.

Practical Actions

The T allele is present in roughly 2–3% of Europeans and is extremely rare in East Asian and African populations, indicating this locus contributes primarily to AD risk in European-ancestry individuals. For carriers, the OR of 1.17 represents a modest but statistically robust elevation in atopic dermatitis risk.

Because the biological mechanism is CTSS-mediated antigen dysregulation and PAR2-driven itch, practical management focuses on reducing the downstream consequences: attenuating type 2 immune skewing, protecting the skin barrier to limit the antigen challenge that CTSS amplifies, and addressing the PAR2-itch axis. Emollient therapy that maintains barrier integrity reduces the antigen load reaching dendritic cells and thus the antigen-presentation amplification that elevated CTSS activity drives.

Serine/cysteine protease inhibitors targeting CTSS are under active investigation as therapeutic targets for atopic dermatitis and asthma — carriers of this locus may be particularly responsive to this class of emerging therapies.

Interactions

Two additional CTSS-region variants (rs146527530 and rs115161931) were identified as independent signals in the same GWAS meta-analysis, at positions 151,059,196 and 151,063,299 (GRCh38) with ORs of 1.27 and 1.18 respectively. These may reflect distinct regulatory mechanisms acting on CTSS or on nearby genes. Co-occurrence of multiple CTSS-locus risk alleles could compound individual risk; compound action evidence across these variants has not yet been formally studied.

Within the broader AD genetic architecture, CTSS operates downstream of the epithelial barrier (FLG, SPINK5, KIF3A) and upstream of adaptive immune polarization (STAT6, IL13, IL4). Individuals with both barrier-gene defects and CTSS-locus risk may face an amplified antigen-presentation burden, as more antigens penetrate the defective barrier and encounter a sensitized CTSS-driven presentation pathway.

The SHMT1 gene encodes serine hydroxymethyltransferase 1, a pyridoxal phosphate (vitamin B6)-dependent enzyme¹¹ pyridoxal phosphate (vitamin B6)-dependent enzyme
SHMT1 requires vitamin B6 as a cofactor that sits at a critical junction in one-carbon metabolism²² one-carbon metabolism
the folate cycle that provides methyl groups for DNA synthesis, repair, and methylation. SHMT1 converts serine and tetrahydrofolate into glycine and 5,10-methylenetetrahydrofolate, supplying one-carbon units for thymidylate synthesis (DNA building blocks) and methylation reactions. The C1420T variant causes a leucine-to-phenylalanine substitution at position 474 of the protein, altering its cellular localization and affecting how efficiently the enzyme channels one-carbon units through different metabolic pathways.

The Mechanism

The Leu474Phe amino acid change affects the enzyme's cellular distribution³³ affects the enzyme's cellular distribution
The T allele alters SHMT1 localization within cells, reducing availability of 5,10-methylenetetrahydrofolate rather than simply destroying its activity. SHMT1 normally shuttles between the cytoplasm and nucleus during DNA replication, providing one-carbon units directly where they're needed. The 1420T variant appears to disrupt this trafficking, causing the enzyme to favor certain metabolic routes over others. Specifically, it may reduce the supply of methylenetetrahydrofolate⁴⁴ reduce the supply of methylenetetrahydrofolate
substrate required by the MTHFR enzyme that converts it to methylfolate for homocysteine remethylation. This creates a metabolic bottleneck: less substrate available for MTHFR, potentially leading to elevated homocysteine if folate intake is marginal.

Intriguingly, individuals with the CC genotype have lower plasma and red blood cell folate levels⁵⁵ individuals with the CC genotype have lower plasma and red blood cell folate levels
Study of neural tube defect families found significantly decreased folate in CC carriers compared to T allele carriers — the opposite of what you might expect given the T allele's functional changes. This paradox likely reflects a compensatory redistribution: the T variant shifts folate derivatives toward different storage forms or compartments rather than simply depleting them. The clinical consequences depend on which metabolic pathway matters most for a given condition.

The Evidence

The most robust data come from cancer association studies⁶⁶ cancer association studies
Multiple meta-analyses with tens of thousands of participants. A meta-analysis of 7,309 lymphoma patients⁷⁷ meta-analysis of 7,309 lymphoma patients
3,232 cases and 4,077 controls across eight studies found the TT genotype modestly increases non-Hodgkin lymphoma risk (OR = 1.18), with borderline significance. The association is stronger for the T allele in general (OR = 1.09, p = 0.025), suggesting a dose-dependent effect. Mechanisms likely involve impaired DNA synthesis or methylation during rapid immune cell proliferation.

Conversely, a meta-analysis of 31,405 solid tumor cases⁸⁸ meta-analysis of 31,405 solid tumor cases
14,409 cases and 16,996 controls from 23 studies revealed the TT genotype protects against breast cancer in Asian populations (OR = 0.79, p = 0.003), though not in Caucasians. A similar protective effect appears for rectal cancer⁹⁹ rectal cancer
Study of 476 rectal cancer patients in Hungary, where TT carriers had 43% lower risk (OR = 0.57). For acute lymphoblastic leukemia¹⁰¹⁰ acute lymphoblastic leukemia
Univariate analysis in adults, the TT genotype conferred a striking 3.3-fold risk reduction (OR = 0.31). These protective effects may arise from altered folate partitioning that reduces availability of nucleotides for rapidly dividing cancer cells.

The cardiovascular story involves gene-gene interactions¹¹¹¹ gene-gene interactions
SHMT1 and MTHFR polymorphisms interact to influence CVD risk. In the Nurses' Health Study, women carrying both SHMT1 TT and MTHFR 677 CT genotypes faced 4.3-fold increased cardiovascular disease risk compared to women with CC for both variants. The mechanism: reduced substrate (5,10-methylenetetrahydrofolate) from SHMT1 TT compounds the impaired enzyme activity from MTHFR 677T, creating a severe bottleneck in homocysteine remethylation. Elevated homocysteine and C-reactive protein together predict worse cardiovascular outcomes¹²¹² Elevated homocysteine and C-reactive protein together predict worse cardiovascular outcomes
Prospective study of 291 stroke patients over 5 years, with combined high levels raising risk 4.67-fold.

Practical Implications

If you carry one or two T alleles, your folate metabolism is functional but may be less efficient at certain steps, particularly the conversion of folate intermediates into methylfolate for homocysteine metabolism. The clinical relevance depends heavily on context — your folate intake, the status of other folate-cycle genes (especially MTHFR), and which tissues are most metabolically active.

For cardiovascular protection¹³¹³ cardiovascular protection
SHMT1 interacts with MTHFR to influence heart disease risk, prioritize methylfolate over synthetic folic acid, especially if you also carry MTHFR 677T or 1298C variants. The SHMT1-MTHFR interaction can significantly elevate homocysteine, an independent risk factor for atherosclerosis. Consider periodic homocysteine testing (ideal range: <10 μmol/L) to monitor whether your folate metabolism is keeping up with demand.

The cancer associations are complex and context-dependent. The T allele may increase risk for blood cancers involving rapid immune cell division, but appears protective against some solid tumors. This isn't a call to avoid or embrace the variant — it's fixed in your DNA — but rather a reminder that optimal folate status matters. Adequate B vitamin intake supports proper DNA synthesis and repair regardless of genotype.

Interactions

SHMT1 C1420T interacts most notably with MTHFR C677T (rs1801133) and A1298C (rs1801131). When SHMT1 TT reduces the supply of 5,10-methylenetetrahydrofolate, and MTHFR 677T reduces the enzyme's ability to convert that substrate, the combined effect significantly impairs methylfolate production and homocysteine remethylation. This gene-gene interaction substantially increases cardiovascular disease risk beyond either variant alone, particularly in the context of marginal folate intake. Individuals with both SHMT1 TT and MTHFR 677 CT or TT genotypes should prioritize methylfolate supplementation and monitor homocysteine levels.

SHMT1 also functions in the same pathway as SLC19A1 G80A (RFC1, rs1051266), the main folate transporter into cells, and MTRR A66G (rs1801394), which recycles methionine synthase. Variants in these genes can compound SHMT1-related inefficiencies by further limiting folate availability or homocysteine remethylation capacity.

Motion sickness is not a matter of imagination or willpower — it has a measurable genetic architecture. The largest GWAS of motion sickness to date (80,494 individuals from 23andMe) identified 35 genome-wide significant loci, and the variant near MUTED on chromosome 6 stands out for pointing directly to the sensory mechanism that makes motion perception possible in the first place: otoliths¹¹ otoliths
calcium carbonate crystals embedded in a gel matrix within the utricle and saccule of the inner ear; they shift under gravity and linear acceleration, bending hair cells to signal head movement to the brain.

MUTED (also called BLOC1S5) encodes a subunit of the biogenesis of lysosome-related organelles complex 1 (BLOC-1). In mice, the homolog of MUTED specifically controls the synthesis of otoliths in the vestibular labyrinth — and mice with muted mutations develop deficient otoconia, the calcium carbonate crystals that constitute the otolith mass, with proportionally impaired gravity receptor responses.

rs2153535 is a regulatory variant approximately 300 kilobases downstream of BLOC1S5 on chromosome 6p24.3. The G allele reaches genome-wide significance for motion sickness susceptibility at p = 2.7×10⁻¹⁸, with a per-allele beta of 0.046. The G allele is common globally (approximately 40%) but shows notable variation across ancestries: nearly 50% in Europeans, only 22% in East Asians.

The Mechanism

The BLOC-1 complex regulates trafficking of membrane proteins to lysosome-related organelles — in the inner ear, this includes the vesicular machinery needed to deposit calcium carbonate onto the otolith membrane during development and maintenance. Impaired BLOC1S5 function in mouse models results in reduced or abnormal otoconia, meaning the gravity-sensing mass in the utricle and saccule is diminished.

The consequence is not deafness — the auditory cochlea is unaffected by these mutations — but a selective impairment of the otolith organs' ability to transduce gravity and linear acceleration signals faithfully. When the vestibular signal is weak or asymmetric, the brain receives ambiguous information about head position and movement. Physiological studies confirm this²² Physiological studies confirm this
Singh et al. 2014 demonstrated elevated vestibular evoked myogenic potential thresholds and higher inter-aural asymmetry ratios in motion sickness-susceptible individuals compared with controls: reduced or asymmetric otolith function is the likely mechanism linking genetic vestibular variants to motion sickness susceptibility.

Motion sickness itself arises from sensory conflict — the brain receives inconsistent signals from the vestibular system, visual system, and proprioception about what motion is occurring. A vestibular system with reduced otolith fidelity generates a noisier signal, increasing the probability of that conflict threshold being crossed during passive movement (car, boat, plane, VR).

The Evidence

Hromatka et al. 2015³³ Hromatka et al. 2015
Genetic variants associated with motion sickness point to roles for inner ear development, neurological processes and glucose homeostasis. Human Molecular Genetics is the founding study: 80,494 participants from 23andMe, 35 genome-wide significant loci, P = 2.7×10⁻¹⁸ at rs2153535. The propensity score built from all 35 SNPs explained 2.9% of variance in motion sickness; individuals in the top 5% had 6.37-fold increased odds of frequent motion sickness. Sex-specific effects were substantial — effects up to three times stronger in women — consistent with known clinical observations that women are more frequently and severely affected by motion sickness.

The genetic overlap between motion sickness and vertigo is supported by Skuladottir et al. 2021⁴⁴ Skuladottir et al. 2021
A genome-wide meta-analysis uncovers six sequence variants conferring risk of vertigo. Communications Biology (48,072 vertigo cases, 894,541 controls), which found that eight motion sickness variants from Hromatka 2015 also associated with vertigo — suggesting shared vestibular pathway architecture underlies both conditions.

The causal biological link between MUTED gene function and inner ear gravity sensing is supported by Jones et al. 2004⁵⁵ Jones et al. 2004
Gravity receptor function in mice with graded otoconial deficiencies. Hearing Research: otoconial-deficient mice including the muted strain showed graded vestibular response impairment proportional to their degree of otolith loss.

Practical Actions

Motion sickness susceptibility from this locus is a property of the vestibular system's baseline signal fidelity, not something modifiable by supplements. The actionable strategies are behavioral and pharmacological: positioning to minimize sensory conflict (front-seat travel, horizon-facing orientation), scopolamine patches before anticipated exposure, and vestibular habituation training (a structured exposure protocol used in aerospace medicine to increase motion sickness threshold). There is emerging evidence that these training protocols produce lasting neuroadaptation even in genetically susceptible individuals.

Interactions

The MUTED locus is one of 35 genome-wide significant motion sickness loci from Hromatka 2015. Other major loci include rs66800491 near PVRL3 (eye development, strongest hit at p = 4.2×10⁻⁴⁴) and rs1195218 near AUTS2 (autism spectrum/neurodevelopment, p = 4.5×10⁻²²). The combination of multiple motion sickness risk alleles compounds susceptibility — the polygenic score across all 35 loci explains 6.37-fold odds in the top 5% versus the bottom 5%. The MUTED locus does not interact with specific drugs through pharmacogenomic mechanisms, but G allele homozygotes who respond poorly to scopolamine are likely best served by vestibular habituation training as an alternative prevention strategy.

The overlap between motion sickness and migraine susceptibility (Hromatka 2015 confirmed the genetic correlation) suggests that vestibular migraine — where migraine attacks trigger vestibular symptoms — may be especially relevant for carriers of both MUTED-region risk alleles and known migraine susceptibility variants.

Glucokinase¹¹ Glucokinase
GCK (hexokinase-4): the enzyme that phosphorylates glucose to glucose-6-phosphate in pancreatic beta cells and hepatocytes, functioning as the pancreas's molecular glucose sensor. Its kinetic properties require high glucose to activate, making it the gatekeeper of glucose-stimulated insulin secretion. (GCK) is one of the most consequential metabolic genes in the human genome. Rare loss-of-function mutations cause MODY2 — lifelong mild fasting hyperglycemia. Activating mutations cause congenital hyperinsulinism. Common intronic variants such as rs4607517 are among the most robustly replicated loci for fasting glucose in large-scale GWAS. rs2268574 is a different intronic variant in the same gene, located 38 nucleotides downstream of exon 7 in intron 7, with a more limited and less consistent evidence record.

The Mechanism

rs2268574 (GRCh38 chr7:44149722; coding-strand notation: c.679+38T>G) sits well within intron 7 of GCK, 38 base pairs downstream of the exon 7 splice donor site. At this distance from the canonical splice site, classical splice-disrupting effects are unlikely. The variant does not alter any glucokinase protein sequence. Its potential functional mechanism — if any — would be regulatory, perhaps through intronic enhancer activity or effects on mRNA secondary structure, but no functional characterization has been published for this specific variant.

The A allele (the GRCh38 reference) is the population-minor allele globally (~43%), while the G allele predominates (~57% worldwide). The A allele is somewhat more common in Europeans (~51%) and South Asians (~56%) than in East Asians (~37%) or Africans (~27%), suggesting some population stratification that could confound association studies not appropriately controlling for ancestry.

The Evidence

The evidence base for rs2268574 is small and inconsistent. A 2014 communication²² 2014 communication
Frigeri HR et al. The polymorphism rs2268574 in Glucokinase gene is associated with gestational Diabetes mellitus. Clin Biochem 2014. PMID:24495862 from a Brazilian group reported an association between the A allele and gestational diabetes mellitus (GDM). However, this study is a brief communication with no published abstract, and independent details such as sample size, odds ratios, and population ancestry are not publicly accessible.

The same research group subsequently tested rs2268574 in obese women with type 2 diabetes and found no significant association³³ no significant association
Frigeri HR et al. Polymorphisms rs144723656, rs2268574, and rs2268575 of the glucokinase gene are not associated with obese women with type 2 diabetes mellitus. Clin Biochem 2016. PMID:26436570. A larger Chinese case-control study with 835 GDM patients and 870 controls also found no significant association⁴⁴ no significant association
She L et al. Association of glucokinase gene and glucokinase regulatory protein gene polymorphisms with gestational diabetes mellitus: a case-control study. Gene 2022. PMID:35276241 between rs2268574 and GDM (P > 0.05). That same study did find the neighboring promoter variant rs1799884 (GCK -30G>A, a distinct locus ~40 kb upstream) to be significantly associated, highlighting that the GCK gene contributes to GDM susceptibility through other variants — but not necessarily through rs2268574.

ClinVar classifies the G allele of rs2268574 as Benign (RCV000832813), reflecting the lack of established pathogenicity. Overall, the evidence for rs2268574 as a functional disease variant is emerging at best — one small positive signal, two negative studies, and no mechanistic characterization.

Practical Actions

The weak and inconsistent evidence for rs2268574 means that no strongly evidence-based genotype-specific intervention can be prescribed. For individuals carrying the A allele (particularly AA homozygotes) with concern about gestational diabetes or glucose metabolism, standard GCK-pathway monitoring applies: fasting glucose and HbA1c provide the most actionable information about glucokinase function regardless of which specific GCK variant is present.

Interactions

rs2268574 is located in the same GCK gene as several other catalogued variants with stronger and better-characterized evidence: rs4607517 (a robustly replicated GWAS locus for fasting glucose in up to 122,744 individuals), and rs1799884 (the GCK -30G>A promoter variant with established GDM association in multiple European cohorts). These represent stronger evidential anchors for GCK-related metabolic risk than rs2268574 itself. rs10278336 is another intronic GCK variant studied in the same Chinese GDM cohort (She 2022) that also showed no independent association with GDM.

CYP2E1 (cytochrome P450 2E1) is the liver enzyme responsible for metabolizing a remarkably diverse set of substrates: acetaminophen (paracetamol), isoniazid (a front-line antibiotic for tuberculosis), ethanol at high concentrations, volatile anesthetics such as halothane, and a range of industrial solvents including benzene, styrene, and trichloroethylene. The rs2515641 variant in exon 8 is [synonymous | a synonymous variant changes the DNA sequence but not the amino acid in the resulting protein] — it substitutes thymine for cytosine at position 1263 in the coding sequence (c.1263C>T), leaving phenylalanine at position 421 unchanged (p.Phe421=). Yet despite producing no amino acid change, it demonstrably reduces how much CYP2E1 the body makes.

The Mechanism

Synonymous variants were once dismissed as functionally inert, but rs2515641 illustrates how altered [codon usage | Codon usage bias: different codons for the same amino acid can differ in translation speed and mRNA stability] can reshape enzyme expression. The c.1263C>T substitution changes a common codon to a rarer one; the result is reduced mRNA stability and slower translation elongation, yielding lower CYP2E1 at both the transcript and protein level. Chen et al. (2020)¹¹ Chen et al. (2020)
Chen K, Guo R, Wei C. Synonymous mutation rs2515641 affects CYP2E1 mRNA and protein expression and susceptibility to drug-induced liver injury. Pharmacogenomics, 2020;21(7):459-470. demonstrated this directly in HepG2 hepatoma cells transfected with lentiviral vectors carrying either the C (wild-type) or T (variant) allele: cells expressing the T allele showed significantly lower CYP2E1 mRNA and protein, and the response of CYP2E1 expression to acetaminophen or triptolide challenge was dramatically altered. rs2515641 is also in complete linkage disequilibrium with [rs2070676 (CYP2E1*1B) | rs2070676, also called CYP2E1*1B, is an intronic variant frequently co-inherited with rs2515641], a variant used as a tag SNP for this genomic region across diverse populations.

The Evidence

For isoniazid toxicity, the most directly clinically documented effect, Yu et al. (2019)²² Yu et al. (2019)
Yu YY et al. Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis. IJERPH, 2019 enrolled 377 patients on a rifapentine-isoniazid regimen for latent tuberculosis. Those carrying the CT or TT genotype had 1.85–1.90-fold increased odds of developing adverse drug reactions (OR 1.850, 95% CI 1.193–2.870 for CT; OR 1.903, 95% CI 1.250–2.898 for CT+TT combined; p=0.003). The T allele itself conferred a 1.70-fold increase (95% CI 1.200–2.421). Isoniazid is metabolized by CYP2E1 into hepatotoxic intermediates; reduced enzyme capacity paradoxically increases systemic isoniazid exposure, raising toxicity risk.

For anti-TB hepatitis more broadly, Tang et al. (2013)³³ Tang et al. (2013)
Tang S et al. Cytochrome P450 2E1 gene polymorphisms/haplotypes and anti-tuberculosis drug-induced hepatitis in a Chinese cohort. PLoS One, 2013 found a minor allele frequency of 20.8% in hepatitis cases vs 18.2% in 356 matched controls (n=4,304 total TB cohort), but this difference was not statistically significant, suggesting that rs2515641 alone does not dominate risk in all populations. Effect size appears to differ substantially between Chinese and Taiwanese cohorts, likely reflecting population-level LD differences and co-exposure patterns.

For acetaminophen, the in vitro Chen et al. data suggest that reduced CYP2E1 expression in T carriers produces less [NAPQI | N-acetyl-p-benzoquinone imine (NAPQI): the toxic metabolite of acetaminophen responsible for liver injury at overdose], the toxic oxidative metabolite responsible for acetaminophen-induced liver failure. However, this does not mean T carriers are fully protected — CYP3A4 and CYP1A2 can compensate at high doses. No large clinical outcome study has confirmed this in humans for this specific SNP.

Population-level [haplotype analysis | Lee et al. (2008) examined 11 CYP2E1 polymorphisms in 2,657 individuals from 50 populations] shows markedly different T-allele frequencies across ancestry groups, with African populations carrying the T allele at ~59% — far above European (~12%) or East Asian (~17%) frequencies — making ancestry a critical variable when interpreting clinical studies predominantly drawn from Han Chinese or European cohorts.

Practical Actions

T allele carriers — particularly CT and TT individuals — face a measurably higher risk of adverse reactions when prescribed isoniazid-containing regimens. Informing a prescribing clinician or infectious disease specialist before starting isoniazid-containing tuberculosis therapy allows proactive liver enzyme monitoring. Dose timing and duration of exposure are key modifiable variables.

For acetaminophen, the practical implication is that standard labelled doses remain appropriate, but T carriers should be especially cautious with high-dose or chronic acetaminophen use, and should avoid stacking it with alcohol, which competes for the same pathway. CYP2E1 is also induced by chronic alcohol use, meaning T carriers who drink regularly may paradoxically upregulate their enzyme back toward normal levels.

Interactions

CYP2E1 expression is strongly induced by chronic ethanol, fasting/ketosis, isoniazid itself, and obesity. A T carrier whose CYP2E1 is already reduced at baseline can have that reduction partially reversed by alcohol-induced enzyme induction. Conversely, combining isoniazid with alcohol in a T carrier amplifies both the metabolic burden and the hepatotoxicity risk. Concurrent use of other CYP2E1 substrates (chlorzoxazone, halothane, certain solvents) with isoniazid or acetaminophen creates additive competitive inhibition that the T carrier's lower enzymatic reserve may not accommodate.

CD36¹¹ CD36
CD36 molecule (also known as fatty acid translocase, FAT, or glycoprotein IV); a multifunctional class B scavenger receptor expressed on platelets, macrophages, adipocytes, enterocytes, skeletal muscle, and taste receptor cells performs a striking number of jobs simultaneously: it transports long-chain fatty acids across cell membranes, senses dietary fat on the tongue and in the gut, mediates uptake of oxidized LDL into macrophages (a key step in atherosclerotic plaque formation), and coordinates chylomicron assembly in intestinal epithelial cells. The rs3211883 variant sits deep in an intron of the CD36 gene on chromosome 7 and, while it does not directly change the protein sequence, it tags a haplotype that appears to modulate CD36 expression levels — with downstream consequences for fat handling and body composition.

The Mechanism

As an intronic variant²² intronic variant
A DNA change located within a non-coding intron; intronic variants typically act by altering regulatory elements, splice enhancers, or gene expression rather than changing the amino acid sequence of the protein, rs3211883 does not directly alter the CD36 protein. Instead, it marks a haplotype block that correlates with differences in CD36 surface expression on platelets — a finding documented in genome-wide association studies of CD36 expression quantitative trait loci. Lower CD36 expression in intestinal enterocytes reduces the protein's ability to coordinate chylomicron³³ chylomicron
Chylomicrons are large lipid-transporting particles assembled in intestinal cells after a fatty meal; they shuttle dietary fat from the gut into the lymphatic system and then into the bloodstream assembly from dietary fatty acids, potentially altering the rate at which long-chain fats move from the gut into circulation. Altered CD36 expression also affects fat taste perception — individuals with lower CD36 expression show reduced oral sensitivity to oleic acid, which may blunt the satiety signals normally triggered by fat consumption and contribute to higher overall energy intake.

The Evidence

The most direct evidence for rs3211883 comes from a study of 646 European adolescents by Bokor et al. (2010)⁴⁴ Bokor et al. (2010)
Bokor S et al. Single-nucleotide polymorphism of CD36 locus and obesity in European adolescents. Obesity (Silver Spring), 2010, which found that carriers of the minor A allele had a significantly elevated odds ratio for obesity of 1.73 (95% CI 1.16–2.59, P=0.007). The association extended to higher BMI and body fat percentage in the validation cohort. A haplotype carrying the minor alleles of four CD36 SNPs — including rs3211883 — was associated with even higher obesity risk (OR 2.28, P=0.0008).

However, a subsequent meta-analysis by Choquet et al. (2011)⁵⁵ meta-analysis by Choquet et al. (2011)
Choquet H et al. Lack of association of CD36 SNPs with early onset obesity: a meta-analysis in 9,973 European subjects. Obesity (Silver Spring), 2011 combining data from 9,973 European subjects found no significant association of rs3211883 with obesity risk (P=0.66). This discrepancy is common in early-generation genetic association studies and reflects the modest effect size of individual intronic variants whose primary role is haplotype-tagging rather than direct functional change.

Stronger evidence emerged from Heni et al. (2011)⁶⁶ Heni et al. (2011)
Heni M et al. Variants in the CD36 gene locus determine whole-body adiposity, but have no independent effect on insulin sensitivity. Obesity, 2011, who genotyped six CD36 SNPs tagging all common variation in the gene in 1,790 Europeans at risk for type 2 diabetes. rs3211883 and rs3211908 were among the variants that significantly associated with waist circumference after Bonferroni correction (P<0.0042). Critically, no independent effect on insulin sensitivity was detected — suggesting the variant affects metabolic risk primarily through its influence on fat distribution rather than direct insulin signaling.

On the molecular side, genome-wide association studies of platelet CD36 surface expression have linked rs3211883 to measured CD36 protein levels (P=0.000298, β=0.69), providing a plausible intermediate mechanism: the variant's haplotype influences how much CD36 protein is produced, which then affects both platelet activation responses to oxidized LDL and intestinal fat handling.

A population-specific finding came from a Japanese cohort study⁷⁷ Japanese cohort study
Kondo N et al. Positive association of common variants in CD36 with neovascular age-related macular degeneration. Aging (Albany NY), 2009 of 109 neovascular AMD cases and 182 controls, where the A allele was actually protective against AMD (OR 0.50, P=2.09×10⁻⁴ after Bonferroni correction). This underscores that the allele's effects are context- and tissue-specific: the same variant that tags increased adiposity risk in Western European populations may have neutral or even protective effects in retinal vasculature in East Asian populations.

Practical Actions

The A allele's primary documented effect is on body fat distribution — specifically waist circumference and overall adiposity. Since CD36 regulates the gut's fat-sensing machinery, individuals with the A allele may benefit from dietary strategies that compensate for altered fat absorption signaling. The protein's established role in long-chain saturated fatty acid transport means that dietary fat composition — not just quantity — is relevant. High saturated fat loads may overwhelm altered CD36 signaling in ways that unsaturated fats do not.

Given the A allele's association with higher platelet CD36 expression in some studies and CD36's role in oxidized LDL uptake by macrophages, monitoring of cardiovascular lipid markers is reasonable for A allele carriers, particularly if other cardiovascular risk factors are present.

Interactions

rs3211883 is in partial linkage disequilibrium with other functional CD36 variants, most notably rs1761667 (associated with oral fat perception and CD36 expression) and rs1527483 (linked to fat taste preferences and triglyceride levels). Individuals carrying the A allele at rs3211883 alongside the A allele at rs1761667 may have compounding impairments in dietary fat sensing that amplify the risk of excess energy intake from high-fat foods. The rs3173798 variant, which sits nearby in the CD36 gene and showed association with AMD in the same Japanese cohort, is in strong LD with rs3211883 in East Asian populations — indicating these two SNPs likely tag the same underlying haplotype in that ancestry group.

The NPSR1 gene encodes the receptor for neuropeptide S (NPS)¹¹ neuropeptide S (NPS)
A 20-amino-acid neuropeptide named for its N-terminal serine residue, expressed in brainstem arousal nuclei including the locus coeruleus and parabrachial area, a powerful arousal-promoting and anxiolytic neuropeptide. NPS is one of a handful of brain signals that simultaneously promotes wakefulness and reduces anxiety — a combination that is pharmacologically unusual, since most wake-promoting compounds (caffeine, amphetamines) tend to increase anxiety rather than decrease it.

The rs324981 variant causes an asparagine-to-isoleucine substitution at position 107 in the first extracellular loop²² extracellular loop
The portion of the receptor protein that protrudes outside the cell and forms part of the ligand-binding pocket of the receptor. This single amino acid change substantially alters how efficiently the receptor responds to its natural ligand, with wide-ranging consequences for sleep timing, sleep duration, and stress reactivity.

The Mechanism

The Ile107 variant (T allele) produces a gain-of-function receptor. In cell-based assays³³ cell-based assays
Reinscheid et al. measured intracellular calcium mobilization and cAMP formation in transfected HEK293 cells, the Ile107 receptor shows approximately 10-fold higher potency for NPS stimulation compared to the Asn107 form — meaning it takes roughly one-tenth the amount of NPS to trigger the same downstream signaling cascade. Crucially, the binding affinity is unchanged; the receptor binds NPS equally well regardless of the variant. The difference lies in how efficiently ligand binding translates into intracellular signaling through G-protein coupled pathways⁴⁴ G-protein coupled pathways
NPSR1 signals via Gq (calcium release) and Gs (cAMP production) pathways, both of which promote neuronal excitation.

Because NPS-producing neurons are concentrated in brainstem arousal centers, a more responsive receptor means stronger arousal signaling from the same amount of endogenous NPS. The net effect is a lower threshold for wakefulness — carriers of the T allele are, in a sense, running a more sensitive wakefulness circuit.

The Evidence

The 2007 Framingham Heart Study GWAS⁵⁵ 2007 Framingham Heart Study GWAS
Gottlieb DJ et al. Novel loci associated with usual sleep duration: the CHARGE Consortium Genome-Wide Association Study. Mol Psychiatry, 2007 first identified rs324981 in a genome-wide screen of 2,848 participants. Each copy of the T allele was associated with a mean bedtime delay of approximately 15 minutes (29.5 minutes for TT homozygotes), consistent with enhanced arousal keeping carriers awake later.

A subsequent actigraphy-based study in 393 elderly adults⁶⁶ actigraphy-based study in 393 elderly adults
Spada J et al. Genetic association of objective sleep phenotypes with a functional polymorphism in the neuropeptide S receptor gene. PLoS ONE, 2014 provided objective sleep measurements. TT homozygotes had significantly shorter sleep duration (P = 0.007) and rest duration (P = 0.003) compared to A-allele carriers, with modest but consistent effect sizes. The bedtime-delay finding from the Gottlieb study was not significantly replicated (P = 0.146), suggesting the primary effect is on sleep duration rather than timing.

Complementary animal data from a 2019 study on a different NPSR1 gain-of-function mutation⁷⁷ 2019 study on a different NPSR1 gain-of-function mutation
Xing L et al. Mutant neuropeptide S receptor reduces sleep duration with preserved memory consolidation. Sci Transl Med, 2019 (Y206H, causing familial natural short sleep) confirmed that NPSR1 gain-of-function broadly reduces sleep need. Mice carrying this mutation slept 71 fewer minutes per day without cognitive impairment — establishing NPSR1 as a genuine sleep-regulating gene, not merely a statistical association.

In a Chinese cohort, Zhao et al. (2020)⁸⁸ Zhao et al. (2020)
Zhao X et al. Gene polymorphisms (rs324957, rs324981) in NPSR1 are associated with increased risk of primary insomnia. Medicine, 2020 found that rs324981 genotype distribution differed significantly between 157 primary insomnia patients and 133 controls (P = 0.04), with the AA genotype overrepresented among insomnia patients (29.9% vs. 19.2%). This seemingly paradoxical finding — the less-active receptor variant associated with insomnia — may reflect that arousal-promoting variants help maintain consolidated sleep, while hypo-function disrupts sleep architecture.

Beyond sleep, the T allele has been associated with panic disorder in two independent studies⁹⁹ panic disorder in two independent studies
Domschke K et al. Neuropeptide S receptor gene — converging evidence for a role in panic disorder. Mol Psychiatry, 2011, heightened cortisol responses to social stress¹⁰¹⁰ cortisol responses to social stress
Kumsta R et al. Neuropeptide S receptor gene is associated with cortisol responses to social stress in humans. Biol Psychol, 2013 (particularly in males), and schizophrenia susceptibility¹¹¹¹ schizophrenia susceptibility
Lennertz L et al. The functional coding variant Asn107Ile of NPSR1 is associated with schizophrenia. Int J Neuropsychopharmacol, 2012 (OR 1.19 for the A allele). These associations reflect the NPS system's dual role in arousal and emotional regulation.

Practical Implications

The rs324981 variant has a modest but real effect on sleep architecture. TT carriers naturally tend toward shorter sleep — not dramatically so (roughly 20 minutes less), but consistently enough to matter over time if combined with external sleep-shortening pressures (late-night screens, caffeine, irregular schedules).

The dual nature of NPS signaling — simultaneously arousal-promoting and anxiolytic — means that T-allele carriers may experience a characteristic pattern: feeling alert and awake without the jitteriness that comes from other stimulants, but also being less inclined to wind down at night. Structuring the evening environment to counteract this enhanced arousal (dimming lights, avoiding stimulation, maintaining a consistent wind-down routine) is more important for carriers than for the general population.

For anxiety, the picture is nuanced. While the T allele is linked to panic disorder risk and heightened cortisol stress responses, NPS itself has anxiolytic properties. The clinical relevance depends on the broader genetic and environmental context. Carriers who experience heightened stress reactivity may benefit from stress-management practices that leverage their naturally efficient arousal system rather than fighting it.

Interactions

NPSR1 rs324981 interacts with the broader circadian and arousal network. Carriers of both the NPSR1 T allele (enhanced arousal) and the CLOCK rs1801260 G allele (evening preference) may experience compounded difficulty initiating sleep, as both variants push toward later bedtimes through different mechanisms — one via arousal promotion, the other via circadian phase delay.

Similarly, carriers who also have the ADORA2A rs5751876 caffeine-sensitivity variant may find that caffeine's arousal-promoting effects layer on top of their already heightened NPS-driven wakefulness, making caffeine timing even more critical.

The NPSR1 T allele's association with panic disorder may interact with variants in stress-response genes, though specific gene-gene interactions at the rs324981 level remain preliminary. Environmental factors (childhood adversity, chronic stress) appear to moderate the anxiety phenotype substantially.

Peroxisome proliferator-activated receptor delta (PPARδ) is the master regulator of fatty acid beta-oxidation¹¹ Fatty acid beta-oxidation is the process of breaking down fat molecules into acetyl-CoA for energy production, primarily in skeletal muscle and heart in skeletal muscle, heart, and liver. Think of it as the dial controlling how efficiently your body uses fat as fuel. PPARδ activation boosts fat burning, preserves insulin sensitivity, improves cholesterol profiles, and supports endurance capacity. The rs3734254 T+294C variant sits in the 3' untranslated region of PPARD and appears to reduce PPARD transcript stability or expression — subtly turning that dial down.

The Mechanism

The T+294C variant lies within the 3' UTR (untranslated region) of the PPARD gene on chromosome 6. The 3' UTR regulates mRNA stability, translational efficiency, and tissue-specific expression. Variants in this region can alter binding sites for microRNAs or RNA-binding proteins, changing how much functional PPARδ protein is ultimately produced. The C allele appears to reduce PPARD expression relative to the common T allele, particularly in metabolically active tissues. Because PPARδ directly drives the transcription of genes encoding enzymes involved in fatty acid oxidation (CPT1, HADHA), glucose uptake, and mitochondrial biogenesis, reduced expression impairs the full range of metabolic benefits downstream.

The Evidence

The clearest human evidence comes from the STOP-NIDDM trial²² STOP-NIDDM trial
Andrulionyte et al. SNPs of PPARD in combination with PGC-1A and PPARG2 predict conversion from IGT to T2D. Diabetes, 2006, which followed 769 individuals with impaired glucose tolerance. In the placebo group, carriers of the rare C allele at rs3734254 combined with the PGC-1A Gly482Ser allele (rs8192678) had up to 2.5-fold higher risk of progressing to type 2 diabetes compared to those carrying the common alleles.

The Tübingen Lifestyle Intervention Program Stefan et al.³³ Stefan et al.
Stefan et al. Genetic variations in PPARD and PPARGC1A determine mitochondrial function and change in aerobic fitness and insulin sensitivity during lifestyle intervention. J Clin Endocrinol Metab, 2007 provided striking evidence of how much PPARD genotype constrains response to exercise and diet: after 9 months of supervised lifestyle intervention, participants carrying minor alleles in both PPARD and PPARGC1A gained only +4% insulin sensitivity, compared to +40% in major allele homozygotes — a tenfold difference in response.

Whole-body MRI data from Thamer et al.⁴⁴ Thamer et al.
Thamer et al. Variations in PPARD determine the change in body composition during lifestyle intervention: a whole-body magnetic resonance study. J Clin Endocrinol Metab, 2008 showed that related PPARD SNPs independently predicted smaller reductions in visceral fat, hepatic fat, and less muscle gain during a lifestyle intervention program in 156 at-risk individuals — connecting this gene family to the distribution, not just amount, of fat.

Interestingly, the CC homozygous genotype was inversely associated with lung and upper aero-digestive tract cancer mortality in a large observational study Yang et al.⁵⁵ Yang et al.
Yang et al. Polymorphisms of peroxisome proliferator-activated receptors and survival of lung cancer and upper aero-digestive tract cancers. Lung Cancer, 2014 (aHR=0.63 for lung cancer; 0.51 for UADT cancers), suggesting context-specific effects that differ between metabolic and oncological outcomes.

Practical Actions

For C allele carriers, the core challenge is that standard-intensity exercise and dietary changes produce a blunted metabolic return. The evidence from Stefan et al. and Thamer et al. points specifically toward the type and intensity of fat metabolism training: higher volumes of prolonged aerobic work at fat-burning intensities (Zone 2), together with a deliberate reduction in saturated fat and total long-chain fat load, may be needed to compensate for lower baseline PPARδ-driven fat oxidation.

Monitoring fasting glucose and insulin periodically gives early warning if metabolic progression is occurring — particularly important given the T2D conversion signal in the STOP-NIDDM trial.

Interactions

rs3734254 interacts most strongly with the PGC-1A Gly482Ser variant (rs8192678 in PPARGC1A) — the STOP-NIDDM data show that the two-gene combination produces risk far exceeding either alone. Within the PPARD gene itself, rs3734254 forms haplotypes with rs2267668, rs2016520, and rs6902123, the three fitness-category PPARD variants associated with aerobic fitness response and athlete performance.

FOXO3 is the most consistently replicated human longevity gene, with associations validated across every major population group. While multiple intronic variants in FOXO3 tag longevity haplotypes, most are statistical proxies — markers in linkage disequilibrium with the true functional variant. rs4946935 is different: it is one of only two FOXO3 variants with direct experimental proof of allele-specific function, making it the mechanistic anchor of the largest FOXO3 longevity haplotype.

Flachsbart et al. 2017¹¹ Flachsbart et al. 2017
Identification and characterization of two functional variants in the human longevity gene FOXO3. Nat Commun. 2017 resequenced the entire FOXO3 locus and genotyped 3,476 long-lived individuals and controls across German, French, and Danish cohorts. From 122 candidate variants, two emerged with both strong association signals and functional evidence: rs12206094 and rs4946935. Of the two, rs4946935 carried the lowest p-value in the combined meta-analysis (OR = 1.19, p = 2.38×10⁻⁵), and was subsequently confirmed as the lead SNP in the largest four-cohort centenarian study conducted to date.

The Mechanism

rs4946935 sits in intron 3 of FOXO3 at chromosomal position 108,679,539 (GRCh38, chromosome 6). The G→A transition creates a de-novo binding site for serum response factor (SRF)²² serum response factor (SRF)
a transcription factor in the MAPK/ERK pathway that responds to growth factor signaling and extracellular stress. Critically, SRF is not constitutively active at this site — its binding and the enhancer activity it drives are specifically and substantially suppressed by IGF-1 treatment in reporter assays.

This IGF-1 reversibility connects rs4946935 directly to the insulin/IGF-1 signaling (IIS) pathway — the most deeply conserved longevity pathway in biology, from yeast and worms to mice and humans. When circulating IGF-1 is high (as during high-protein feeding, rapid growth, or insulin resistance), IIS suppresses FOXO3 through AKT-mediated phosphorylation and cytoplasmic sequestration — and the same signaling environment also suppresses the rs4946935 SRF enhancer. When IGF-1 is low (fasting, caloric restriction, plant-protein predominance), both the SRF enhancer and FOXO3 nuclear activity are released simultaneously, compounding the longevity signal.

The rs4946935 haplotype is structurally and mechanistically distinct from the other major FOXO3 longevity locus at rs2802292, which operates through HSF1 (heat shock factor 1)³³ HSF1 (heat shock factor 1)
a stress-response transcription factor activated by heat, oxidative damage, and proteotoxic stress. HSF1 responds to cellular damage stress; SRF responds to nutrient and growth factor status. They are independent FOXO3 regulatory switches — additive in effect, complementary in stimulus.

In line with the enhancer model, eQTL analyses confirm that the A allele of rs4946935 is associated with higher FOXO3 mRNA expression across multiple human tissues. The A allele is also in strong linkage disequilibrium (r²=0.96) with rs1935949, another shipped FOXO3 longevity variant — the two variants tag the same regulatory haplotype and report concordant results in virtually all genome data.

The Evidence

The primary evidence comes from three layers: functional assays, European cohort replication, and cross-population meta-analysis.

Functional validation: Flachsbart et al. 2017⁴⁴ Flachsbart et al. 2017 confirmed SRF binding to the A allele by electrophoretic mobility shift assay (EMSA), then demonstrated allele-specific enhancer activity in luciferase reporter assays. Critically, adding IGF-1 to the culture medium significantly reduced reporter activity in cells with the longevity A allele, confirming that the enhancer is responsive to the same IIS pathway that regulates FOXO3 protein localization. This dual convergence — both the enhancer and the protein — on the same nutrient-sensing pathway is a striking mechanistic coherence.

Cohort replication: The German discovery cohort (1,109 LLI ≥95 years including 594 centenarians, 918 controls aged 60–75) showed OR = 1.35 for centenarians (p = 0.0003). This replicated in a French cohort (1,264 LLI aged 91–115 years, 1,830 controls) at OR = 1.14, p = 0.022, and trended in the same direction in a Danish cohort (643 LLI, 746 controls, OR = 1.14, p = 0.127).

Cross-population meta-analysis: Bae et al. 2018⁵⁵ Bae et al. 2018
Effects of FOXO3 Polymorphisms on Survival to Extreme Longevity in Four Centenarian Studies. J Gerontol A Biol Sci Med Sci. 2018 pooled data from the Long Life Family Study, New England Centenarian Study, Southern Italian Centenarian Study, and Longevity Genes Project — 2,072 cases and 6,194 controls. rs4946935 emerged as the SNP with the lowest p-value across all FOXO3 variants tested (OR = 1.20, p = 3.20×10⁻⁵). The A allele was enriched in long-lived individuals in all four cohorts.

Important nuance: The Bae 2018 analysis also examined whether rs4946935 predicts survival to the most extreme ages (beyond the 1st percentile for the 1900 birth cohort). The survival advantage was statistically significant for reaching very old age (~90–99 range) but not for survival past that threshold specifically — suggesting this variant helps people reach advanced old age, but centenarian status at the extreme tail reflects additional factors.

Practical Implications

The IGF-1 responsiveness of this SRF enhancer is the clearest dietary signal in the FOXO3 longevity genetics literature. Interventions that lower circulating IGF-1 specifically activate this regulatory mechanism. The most evidence-based dietary approach is a shift toward plant protein: animal protein (especially dairy and red meat) is the strongest macronutrient driver of circulating IGF-1; plant proteins (legumes, tofu, nuts) produce substantially lower IGF-1 responses. Controlled feeding studies show serum IGF-1 can fall 15–25% within weeks of shifting to predominantly plant protein while maintaining adequate total protein intake.

Time-restricted eating and periodic fasting also lower IGF-1 acutely and chronically, providing additional windows during which the SRF enhancer at rs4946935 is maximally active. These interventions are complementary to the exercise-based HSF1 activation that benefits the rs2802292 longevity locus — carriers of protective alleles at both sites can stack both dietary (IIS reduction) and stress-response (hormetic exercise) strategies.

The A allele frequency of ~30% in Europeans means the majority of people of European descent carry at least one copy (AG ~42%, AA ~9%). This is not a rare variant — it is a common regulatory polymorphism with replicated functional evidence, placing it among the most actionable findings in longevity genetics.

Interactions

rs4946935 and rs1935949 are in near-perfect LD (r²=0.96) and tag the same regulatory haplotype. Individuals with genome data from chips that captured one but not the other will receive equivalent information from either variant. The SRF enhancer mechanism described above applies to both as proxies of the same functional allele.

rs4946935 and rs2802292 are in different haplotype blocks and respond to different cellular signals: the SRF enhancer at rs4946935 responds to nutrient status (low IGF-1 during fasting or plant-protein diet), while the HSF1 enhancer at rs2802292 responds to cellular stress (heat, oxidative damage, proteotoxic stress). Carriers of protective alleles at both sites activate FOXO3 through two independent mechanisms, suggesting additive longevity benefit that targets different lifestyle interventions simultaneously.

rs12206094 is the second independently validated functional FOXO3 variant from the Flachsbart 2017 study. It involves CTCF binding rather than SRF, placing it in a distinct regulatory context. The combined genotype OR for carrying longevity alleles at both rs12206094 and rs4946935 substantially exceeds either alone.